RBC and Key Organics Announce Drug Discovery Collaboration
News Sep 05, 2005
Reaction Biology Corporation ("RBC") and Key Organics Ltd. have announced that they have created a Joint Venture ("JV") to engage in high throughput drug discovery.
The purpose of the JV is to identify a series of compounds with the potential of becoming drugs with further research, and then to partner or sell the compounds to pharmaceutical companies interested in the selected targets.
Key Organics supplies diverse sets of compounds synthesized in-house using classical organic procedures optimized for primary screening of druggable targets.
RBC's DiscoveryDot™ microarray technology is designed to reduce screening volumes to one nanoliter size, allowing large scale screening.
Key Organics will provide compounds for screening against these targets using RBC's DiscoveryDot™ screening technology.
Key Organics will then provide additional chemical analysis and compound synthesis, and RBC will perform additional screening and profiling. The companies will then collaborate on further development of selected compounds.
3-D Printed Sugar Scaffolds Offer Sweet Solution for Tissue EngineeringNews
University of Illinois engineers built a 3-D printer that offers a sweet solution to making detailed structures that commercial 3-D printers can’t: Rather than a layer-upon-layer solid shell, it produces a delicate network of thin ribbons of hardened isomalt, the type of sugar alcohol used to make throat lozenges.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018